Excess Cardiovascular Risk in Gout

Save

A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.

Can Biomarkers Improve Cardiovascular Risk Assessments in RA?

Save

The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis. A subsequent analysis of these patients showed several candidate biomarkers that may correlate with baseline and treatment‐associated changes in arterial inflammation in patients with RA. 

Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease

Save

The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, particularly in the 5 to 10 years preceding the start of symptoms, finds research published in the open access journal RMD Open.

EGPA: Benralizumab or Mepolizumab

Save

A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that Benralizumab (BEN) was noninferior to mepolizumab (MEP) for the induction of remission of patients with relapsing or refractory Eosinophilic granulomatosis with polyangiitis (EGPA).

Behçet’s Syndrome

Save

A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches.

PAPA (pyogenic arthritis, pyoderma gangrenosum & acne) syndrome is a hereditary autoinflammatory Dz caused by dominant mutation in PSTPIP1 (triggers IFN-γ-mediated pyrin induction & IL-18 release; can be Tx by JAK inhibition) https://t.co/fy0MnwDA5U https://t.co/l8n2EwgV0t